• Chronic Pain
  • Contact
  • Depression
  • Home
  • Privacy Policy
  • PTSD
  • Terms and Conditions
  • Video
Saturday, June 21, 2025
  • Login
Ketamine News
Advertisement
  • Home
  • Depression
    ketamine news

    Bronner’s Magic Soaps Becomes The First Company to Offer Ketamine-Assisted Therapy as Part of Employees’ Health Benefits

    ketamine news

    Popular Soap Company–Dr. Bronner’s– Plans To Explore The Psychedelic Space

    ketamine news

    Psychedelic and Plant Medicine Decriminalization Efforts Spread to the Midwest.

    ketamine news

    What There is to Know About Ketamine vs. Electroconvulsive Therapy (ECT)

    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    ketamine news

    Aggregate Study on the Efficacy of Ketamine to Treat Depression Shows Promising Results.

    Flow Integrative - Christi Myers

    Provider Spotlight – Christi Myers, Flow Integrative

    How To Help A Depressed Person

    How To Help A Depressed Person

  • Chronic Pain
    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    Ketamine: A Paradigm Shift in Pain Management

    Ketamine: A Paradigm Shift in Pain Management

    ketamine treatment for depression

    Amidst An Opioid Crisis, Ketamine Has the Potential To Save Lives

    Ketamine for pain

    Multi-Day Low Dose Ketamine Infusion For The Treatment Of Complex Regional Pain Syndrome

    ketamine for chronic pain

    End Chronic Back Pain with Ketamine for a Fuller Life

    ketamine for pain

    What You Should Know About Rheumatoid Arthritis

    ketamine for pain

    Myofascial Pain Syndrome: Symptoms, Causes, and Treatment

    ketamine for pain

    A sweet reprieve: Ketamine helps to relive phantom limb pain

  • PTSD
    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    veterans day

    Veterans’ Day: What Does PTSD Look Like In Veterans?

    PTSD awareness month

    PTSD Awareness Month: What Can I Do To Help?

    Trump Orders ‘a lot’ of Ketamine for Depressed Veterans

    Will Ketamine Be A Breakthrough Drug for PTSD?

    Ketamine to treat ptsd

    PTSD Sufferers ‘Healed’ With New Ketamine Infusion Therapy?

    ketamine to treat PTSD

    VA Uses Ketamine To Treat PTSD Effectively

    ketamine to treat ptsd

    Ketamine can help treat PTSD

  • Video
  • Ketamine Directory
  • Ketamine Media
  • Contact
No Result
View All Result
  • Home
  • Depression
    ketamine news

    Bronner’s Magic Soaps Becomes The First Company to Offer Ketamine-Assisted Therapy as Part of Employees’ Health Benefits

    ketamine news

    Popular Soap Company–Dr. Bronner’s– Plans To Explore The Psychedelic Space

    ketamine news

    Psychedelic and Plant Medicine Decriminalization Efforts Spread to the Midwest.

    ketamine news

    What There is to Know About Ketamine vs. Electroconvulsive Therapy (ECT)

    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    ketamine news

    Aggregate Study on the Efficacy of Ketamine to Treat Depression Shows Promising Results.

    Flow Integrative - Christi Myers

    Provider Spotlight – Christi Myers, Flow Integrative

    How To Help A Depressed Person

    How To Help A Depressed Person

  • Chronic Pain
    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    Ketamine: A Paradigm Shift in Pain Management

    Ketamine: A Paradigm Shift in Pain Management

    ketamine treatment for depression

    Amidst An Opioid Crisis, Ketamine Has the Potential To Save Lives

    Ketamine for pain

    Multi-Day Low Dose Ketamine Infusion For The Treatment Of Complex Regional Pain Syndrome

    ketamine for chronic pain

    End Chronic Back Pain with Ketamine for a Fuller Life

    ketamine for pain

    What You Should Know About Rheumatoid Arthritis

    ketamine for pain

    Myofascial Pain Syndrome: Symptoms, Causes, and Treatment

    ketamine for pain

    A sweet reprieve: Ketamine helps to relive phantom limb pain

  • PTSD
    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    veterans day

    Veterans’ Day: What Does PTSD Look Like In Veterans?

    PTSD awareness month

    PTSD Awareness Month: What Can I Do To Help?

    Trump Orders ‘a lot’ of Ketamine for Depressed Veterans

    Will Ketamine Be A Breakthrough Drug for PTSD?

    Ketamine to treat ptsd

    PTSD Sufferers ‘Healed’ With New Ketamine Infusion Therapy?

    ketamine to treat PTSD

    VA Uses Ketamine To Treat PTSD Effectively

    ketamine to treat ptsd

    Ketamine can help treat PTSD

  • Video
  • Ketamine Directory
  • Ketamine Media
  • Contact
No Result
View All Result
Ketamine News
Home Esketamine

SLS-002 Intranasal Ketamine Depression Drug Granted Fast Track Status by FDA

Ketamine News by Ketamine News
November 19, 2019
in Esketamine, Featured, Ketamine in The News
0
Seelos FDA Ketamine News

Seelos FDA Ketamine News

0
SHARES
415
VIEWS
Share on FacebookShare on Twitter

 

Seelos Therapeutics Inc (NASDAQ:SEEL) stock soared Monday after its SLS-002 intranasal ketamine depression drug aimed at patients with post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) at risk of committing suicide, was granted fast track designation by US regulators.

The US Food and Drug Administration (FDA) granted the status for the development of the drug for the treatment of Acute Suicidal Ideation and Behavior (ASIB) in patients with major depressive disorder.

Investors responded well, sending shares in the New York clinical-stage biopharmaceutical company nearly 10.2% higher to $0.95 in morning trade.

“The decision by the FDA to grant fast track designation to SLS-002 underscores the significant unmet medical need for patients with Acute Suicidal Ideation and Behavior in major depressive disorder,” said Seelos CEO Raj Mehra.

“We will be working diligently in close collaboration with the FDA to finalize the protocol for the proof of concept study and future clinical development,” added Mehra.

Speeds up drug development

The FDA’s fast track program is designed to speed up the development and review of new medicines for the treatment of serious conditions where there is an unmet need.

“While I was a psychiatrist working in an academic teaching hospital, I saw and treated many of these patients. The limited medical treatment options have been a source of great frustration to patients, their families, and their healthcare practitioners,” said Tim Whitaker, head of R&D at Seelos Therapeutics.

“SLS-002 has promise to help address this critical unmet need. We are encouraged by the FDA’s fast track designation as this moves the program forward in a meaningful way,” he added.

Data from a Phase I study of SLS-002 to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interactions are expected in the first quarter of 2020.

Suicide represents the tenth leading cause of death in the US, according to the Centers for Disease Control and Prevention with nearly 1.3 million adults attempting suicide each year and 45,000 of such attempts result in death.

Wall Street is bullish that Seelos Therapeutics’ SLS-002 intranasal ketamine depression drug under development is safe and will reach millions of patients with post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) at imminent risk of committing suicide.

Far more potent 

Johnson & Johnson’s (NYSE:JNJ) J&J’s nasal spray SPRAVATO and Seelos’ SLS-002 nasal spray both have formulations of ketamine, with subtle differences. J&J’s nasal spray contains the esketamine compound, which is one half of the ketamine compound. However, Seelos Therapeutics’ nasal form of racemic ketamine is made of two mirror-image molecules and is likely to be given at a lower dose because it is far more potent.

A Zanos publication shows in the animal depression model, that racemic/R ketamine has more potency and minimal side effects versus S-ketamine. The R isomer also lacks the negative psychoactive effects associated with ketamine.

 

Original Article: https://www.proactiveinvestors.com/companies/news/907281/seelos-stock-soars-after-its-sls-002-intranasal-ketamine-depression-drug-granted-fast-track-status-by-fda-907281.html

Previous Post

‘Nothing less than transformational:’ Ketamine brings relief to people with severe depression

Next Post

‘Impressed With Impact’ of Ketamine in Cancer Palliative Care

Next Post
Cancer Treatment Ribbon

'Impressed With Impact' of Ketamine in Cancer Palliative Care

Browse by Category

  • A Day in the Life
  • Esketamine
  • Featured
  • Ketamine Dictionary
  • Ketamine for Anxiety
  • Ketamine for Depression
  • Ketamine for Pain
  • Ketamine for PTSD
  • Ketamine in The News
  • Ketamine Treatment
  • Mental Health
  • Psychedelic Medicine
  • Suicide Prevention
  • Uncategorized
ketamine news
Privacy Policy | Terms and Conditions

Categories

  • A Day in the Life
  • Esketamine
  • Featured
  • Ketamine Dictionary
  • Ketamine for Anxiety
  • Ketamine for Depression
  • Ketamine for Pain
  • Ketamine for PTSD
  • Ketamine in The News
  • Ketamine Treatment
  • Mental Health
  • Psychedelic Medicine
  • Suicide Prevention
  • Uncategorized

Recent Posts

  • Ketamine Decoded: New Study Sheds Light on Its Powerful Brain and Mood Effects
  • Capturing the Ketamine Experience in Real Time: A First-of-its-Kind Academic Paper from Denovo Therapy
  • A Group of D.C. Advocacy Groups Have Joined Hands to Push For Drug Policy Reform in the Nation’s Capital
  • Connecticut Approves a Bill That Could Pave Way for the Use of Psychedelic Substances to Treat Mental Health Illnesses
  • ‘Magic Mushrooms’ Look Set to Follow in the Footsteps of Cannabis
  • Chronic Pain
  • Contact
  • Depression
  • Home
  • Privacy Policy
  • PTSD
  • Terms and Conditions
  • Video

© 2025 Ketamine News

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Depression
  • Chronic Pain
  • PTSD
  • Video
  • Ketamine Directory
  • Ketamine Media
  • Contact

© 2025 Ketamine News